Log In
Print
BCIQ
Print
Print this Print this
 

surotomycin (CB-315) (formerly CB-183,315)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionOral antibacterial lipopeptide
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentPhase III
Standard IndicationDiarrhea (infectious)
Indication DetailsTreat Clostridium difficile-associated diarrhea (CDAD)
Regulatory Designation

U.S. - Fast Track (Treat Clostridium difficile-associated diarrhea (CDAD));
U.S. - Qualified Infectious Disease Program (Treat Clostridium difficile-associated diarrhea (CDAD))

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today